JNJ · Johnson & Johnson · Investor Relations

Low rates of rash, blood clots and administration-related reactions were observed with subcutaneous treatment and prophylaxis Fewer than 1% of patients discontinued treatment due to treatment-related events at one year New findings from Johnson & Johnson build on the MARIPOSA survival benefit and strengthen evidence for RYBREVANT FASPRO plus LAZCLUZE as first-line treatment Johnson & Johnson (NYSE:JNJ) today announced new results from the Phase 2b COPERNICUS study evaluating how subcutaneous RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib), with less frequent dosing and prophylactic strategies, can improve the treatment experience for patients with previously untreated advanced non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor ( EGFR ) mutations. Early results show consistently low rates across key treatment-related events and treatment discontinuation. 1 COPERNICUS was designed to reflect everyday clinical

RYBREVANT plus chemotherapy demonstrates durable benefit with a differentiated approach that dual-targets EGFR and MET Results mark significant progress for a patient population with poor outcomes and a historical five-year survival rate of just 8% Johnson & Johnson (NYSE: JNJ) today announced results from the final overall survival (OS) analysis of the Phase 3 PAPILLON study evaluating first-line intravenous (IV) RYBREVANT (amivantamab-vmjw) plus carboplatin-pemetrexed chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( EGFR ) exon 20 insertion (Ex20ins) mutations. Patients treated with the combination achieved a median OS of nearly three years (34.3 months), compared with 27.9 months for chemotherapy alone. The combination extended median OS by more than six months, despite 76 percent of eligible patients in the chemotherapy arm crossing over to second-line RYBREVANT after disease

New 2-week reusable contact lens brings advanced ACUVUE OASYS MAX technologies to deliver superior comfort and visual clarity to patients, even at day 14 *†1 Expands the ACUVUE OASYS MAX portfolio with an advanced option for reusable contact lens wearers Designed to meet the growing demand for lasting comfort and clear vision in today’s screen-intensive world *†1 Johnson & Johnson (NYSE: JNJ) today announced that it has received CE Marking for ACUVUE OASYS MAX 2-Week,*** a new reusable contact lens featuring proprietary MAX technologies designed to deliver superior comfort and visual clarity, even at day 14. *†i¥1 The lens will be rolled out in select European countries later this year with wider market rollout in 2027. Globally, 140 million people wear contact lenses, with one in two choosing a reusable lens, 2 and comfort remains their leading priority. 3 With the continued rise in everyday use of digital devices and exposure to blue-violet light, more demands are being placed

Johnson & Johnson (NYSE: JNJ) today announced that 24 abstracts featuring clinical data and real-world evidence across the neuropsychiatry portfolio will be presented at the 2026 Psych Congress Annual Meeting (September 15-19, New Orleans, LA). Among the featured presentations are new pivotal Phase 3 data evaluating the efficacy and safety of CAPLYTA ® (lumateperone) in bipolar mania, alongside additional CAPLYTA ® data across bipolar depression and major depressive disorder that further reinforce the breadth of studies for the asset across mood disorders. Data evaluating the effect of SPRAVATO ® (esketamine) CIII nasal spray on depressive symptoms such as anhedonia, and Phase 3 clinical trial data for seltorexant in major depressive disorder (MDD) with insomnia symptoms will also be presented. Together, the presentations reflect the Company's continued commitment to advancing research across mood disorders, with a focus on areas where patients and clinicians still face

Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17 th , 2026. Management will participate in a Fireside Chat at 12:00 p.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. Media contact: [email protected] Investor contact: [email protected] Source: Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, October 13th to review third-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Ryan Koors, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team. Investors and other interested parties can access the webcast/conference call in the following ways: The webcast and presentation material are accessible at Johnson & Johnson’s website www.investor.jnj.com . A replay of the webcast will be available approximately three hours after the conference call concludes. By telephone: for both “listen-only” participants and those financial analysts who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is

IMAAVY is an immunoselective FcRn blocker designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies while also preserving B-cell function Warm autoimmune hemolytic anemia is a rare, life-threatening disease in which autoantibodies cause the destruction of red blood cells, leading to severe anemia and debilitating fatigue The approval is based on the pivotal Phase 2/3 study which demonstrated durable hemoglobin response a A mean increase in hemoglobin of 1 g/dL at Week 1 b and improvement in FACIT-Fatigue c score at Week 24 were observed in IMAAVY-treated patients d Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY ® (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) – a rare, life-threatening autoantibody disease – in adults and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. The approval, which follows FDA Priority Review

Johnson & Johnson (NYSE: JNJ) will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14th, 2026. Management will participate in a Fireside Chat at 11:30 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com . An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. Media contact: [email protected] Investor contact: [email protected] Source: Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9 th , 2026. Management will participate in a Fireside Chat at 11:00 a.m. Eastern Time. A live audio webcast of the presentation will be accessible through Johnson & Johnson’s Investor Relations website at www.investor.jnj.com . An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. Media contact: [email protected] Investor contact: [email protected] Source: Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) today announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine following a distinguished career and over 21-year tenure at Johnson & Johnson. Under her leadership, the Company’s Innovative Medicine business grew to more than $60 billion in annual revenue and strengthened its position as one of the most respected and successful pharmaceutical businesses in the world. Tom Cavanaugh, EVP, Worldwide Chairman Innovative Medicine, Johnson & Johnson Jennifer will be succeeded by Tom Cavanaugh who currently serves as Company Group Chairman, North America, Innovative Medicine. Tom brings nearly three decades of biopharmaceutical experience and leadership across therapeutic areas, functions and geographies to the role. Together they will ensure a smooth transition that enables continued success. Tom will join the Johnson & Johnson Executive Committee, effective September 1,

Priority Review reinforces the significant potential of subcutaneous amivantamab in recurrent or metastatic head and neck cancer, where the current five-year survival rate is only 15 percent Patients achieved rapid, deep and durable responses, including a 42 percent overall response rate with one-third achieving a complete response Subcutaneous amivantamab is the only therapy in head and neck cancer engineered to target both EGFR and MET , proven drivers of tumor growth and treatment resistance Johnson & Johnson (NYSE:JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for subcutaneous amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). If approved, it would provide a new treatment for patients whose disease has progressed following platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. Priority Review is

Broadens capabilities in targeting pan-KRAS and other drivers of hard-to-treat cancers Adds novel degrader antibody conjugate platform designed to address key limitations of existing therapies Advances leadership in next-generation antibody engineering to accelerate oncology innovation Johnson & Johnson (NYSE: JNJ) today announced the successful completion of its acquisition of Firefly Bio, Inc., a biotechnology company advancing its proprietary Firelink™ degrader antibody conjugate (DAC) platform, for $1 billion in cash. The Firelink™ DAC platform expands Johnson & Johnson’s oncology portfolio and advances its ambition to develop targeted therapies for some of the most prevalent and difficult-to-treat solid tumors, including KRAS-driven cancers, where patients continue to face significant unmet need 1 . With the close of the transaction, Johnson & Johnson further deepens its capabilities in next-generation antibody engineering and broadens its strategy for tackling

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated disease Novel in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments with durable, disease-modifying, and curative potential Strengthens Johnson & Johnson's leadership in immunology and CAR-T innovation Grants Johnson & Johnson an exclusive option to acquire Sail Johnson & Johnson 1 (NYSE: JNJ) today announced strategic agreements and collaboration with Sail Biomedicines (Sail), a biotechnology company developing in vivo CAR-T therapies for immune-mediated diseases. Johnson & Johnson will collaborate with Sail to advance its lead immune-mediated disease program and broader platform technology, with incentives to expand the application of Sail's in vivo CAR-T platform across additional therapeutic targets over time. Johnson & Johnson 2 will also make an equity investment in Sail.

Follows Favorable Multi-District Litigation Court Causation Ruling and the Company’s Successful Strategy to Defend Each Case Efficient Conclusion to the Talc Litigation that Eliminates Expense Associated with Litigating Remaining Roughly 76,000 Ovarian Talc Claims Johnson & Johnson (NYSE: JNJ) (the "Company") today announced that it has reached an agreement for a comprehensive resolution of the remaining talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings, conditioned on, among other things, the express participation of at least 95% of the remaining claims. The proposed resolution follows a favorable ruling by the MDL court, and acknowledgment by plaintiffs’ counsel, regarding plaintiffs’ inability to prove that the Company’s talc products caused any particular claimant’s ovarian cancer (“specific causation”). “After decades of litigation and full vetting of the science in an extensive hearing, plaintiffs

Investigational MonumenTAL-6 trial is the first and only Phase 3 study of a dual antigen, BCMA and GPRC5D targeting regimen in relapsed/refractory multiple myeloma Fifth positive Phase 3 study evaluating Johnson & Johnson's multiple myeloma T-cell therapy portfolio in second line, further strengthening the company's leadership and commitment to advancing immunotherapy-based regimens earlier in the treatment journey Johnson & Johnson (NYSE: JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the three-arm investigational Phase 3 MonumenTAL-6 study evaluating TECVAYLI ® (teclistamab-cqyv) + TALVEY ® (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and TALVEY ® + pomalidomide in adult patients with relapsed or refractory multiple myeloma (RRMM) who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide. 1 The study demonstrated statistically significant and clinically

Built to open new possibilities in surgery, OTTAVA™ creates a new category in soft tissue robotics System authorized for use in multiple procedures in general surgery within the upper abdomen System features are designed to enable surgical teams and hospitals to expand OR capacity, streamline clinical workflows, and elevate surgical performance Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for the OTTAVA™ Robotic Surgical System, the world’s first table-integrated soft tissue robotic system. The system received marketing authorization for multiple procedures in general surgery, including Roux-en-Y gastric bypass, gastrectomy, cholecystectomy, splenectomy, gastric sleeve, small bowel resection, appendectomy, lysis of adhesions, fundoplication, and hiatal hernia repair. “We are pioneering a new category of surgical robotics with OTTAVA,” said Tim Schmid, Executive Vice President, Worldwide Chairman, MedTech,

New branded recognition will spotlight the care, innovation and grit of U.S. healthcare professionals making a meaningful difference for patients, colleagues and communities. The collaboration will recognize healthcare leaders helping strengthen care amid growing pressure on health systems. Nominations will open on July 16, 2026 and close at 5:00 p.m. ET on August 28, 2026. Johnson & Johnson (NYSE: JNJ) today announced with TIME the launch of the Healthcare Champion of the Year. The new branded recognition will honor healthcare professionals in the U.S., selected by Johnson & Johnson and a panel of industry experts, whose care, innovation and grit are driving health system change to advance better care for all. Nominations for the inaugural TIME Healthcare Champion of the Year, in partnership with Johnson & Johnson, a branded award, will open July 16, 2026 at www.jnj.com/healthcare-champion-of-the-year and close by 5:00 p.m. ET on August 28, 2026. The honoree will be

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on September 8, 2026 to shareholders of record at the close of business on August 25, 2026. The ex-dividend date is August 25, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ . Media contact: [email protected] Investor contact: <br

2026 Second-Quarter reported sales growth of 6.6% to $25.3 Billion with operational growth of 5.6%* and adjusted operational growth of 5.7%* 2026 Second-Quarter earnings per share (EPS) of $2.27 and adjusted EPS* of $2.90 Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.1 Billion or 7.3% at the midpoint, and increasing adjusted EPS* guidance by $0.13 to $11.68 or 8.2% at the midpoint. The adjusted operational EPS* is increasing by $0.18 to $11.58 or 7.3% at the midpoint Advancing significant innovation for patients with approvals of TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis, CAPLYTA for the prevention of relapse in schizophrenia, and Dual Energy THERMOCOOL SMARTTOUCH SF platform; fortifying future with data from RYBREVANT FASPRO in advanced head and neck cancer, TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma, and OTTAVA

Dual Energy THERMOCOOL SMARTTOUCH SF Platform brings pulse field and radiofrequency energy together in a single catheter. Integrated with the CARTO ecosystem, the platform gives physicians greater versatility to tailor treatment based on patient anatomy and case complexity.i Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) approved the Dual Energy THERMOCOOL SMARTTOUCH SF Platform (DE STSF), an integrated catheter ablation solution that enables electrophysiologists to deliver both radiofrequency (RF) and pulsed field (PF) energy through a single catheter. i Dual Energy THERMOCOOL SMARTTOUCH SF Catheter “The FDA approval of the Dual Energy THERMOCOOL SMARTTOUCH SF Platform is another important milestone in what has been an incredible pace of innovation for our business,” said Michael Bodner, Company Group Chair, Electrophysiology & Neurovascular, MedTech, Johnson & Johnson. “Our goal has always been to put the best possible

RAYNHAM, Mass. – (June 29, 2026) – DePuy Synthes, a global leader in orthopaedic technologies and solutions, today announced the appointment of Christina Zamarro as Chief Financial Officer, DePuy Synthes, effective July 13, 2026. Zamarro brings over 25 years of financial leadership experience serving in multitude of roles across treasury, investor relations, FP&A and accounting. She joins DePuy Synthes from the Goodyear Tire & Rubber Company, a global manufacturer, where she most recently served as the Chief Financial Officer. “I am excited to welcome Christina to the DePuy Synthes team,” said Namal Nawana, Worldwide President, DePuy Synthes. “With more than two decades of financial leadership, she brings deep experience managing global and complex transformation programs. I look forward to partnering closely with Christina as we continue building on our momentum.” Throughout her career, Christina has advanced through leadership roles spanning treasury, investor relations, and

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+ a , anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including those early in their disease, participants with lower symptom burden and those who experienced common infections To address an important evidence gap, the PETUNIAc study design will be presented – demonstrating the innovative way pregnancy outcomes data will be collected following treatment with IMAAVY IMAAVY, an immunoselective neonatal Fc receptor (FcRn) blocker, is designed to target and reduce pathogenic immunoglobulin G (IgG) autoantibodies associated with generalized myasthenia gravis (gMG) Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY ® (nipocalimab-aahu) throughout clinically relevant points in the generalized myasthenia gravis (gMG) treatment journey. The analyses

Investment includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the Company’s U.S. Vision operations, enhance supply chain resilience, and meet the needs of more than 40 million patients Investment is part of the Company’s ongoing $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029 Building on more than 40 years of leadership in Florida, the investment supports 3,500 Jacksonville employees and strengthens Johnson & Johnson’s $6 billion annual economic impact across the state Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced an investment of more than $1 billion in Jacksonville, Florida to strengthen its Vision operations by scaling U.S.-based manufacturing, packaging and distribution capabilities. Johnson & Johnson's U.S. Vision manufacturing and supply chain operations in

TALVEY® plus DARZALEX FASPRO ® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 months MonumenTAL-3 is the third positive study in recent months from Johnson & Johnson's bispecific portfolio and is the first Phase 3 study of a GPRC5D bispecific investigational combination Results reinforce Johnson & Johnson's leadership in multiple myeloma, advancing bispecific combinations earlier in the treatment journey, and expanding options to match the right treatment to the right patient and stage of disease Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced results from the investigational Phase 3 MonumenTAL-3 study showing that TALVEY ® (talquetamab-tgvs), a GPRC5D bispecific antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up